Skip to content
DataLookout
Menu

NCT07649954

A Study to Evaluate How Multiple Doses of Itraconazole Interacts With Nacresertib in Healthy Adult Participants

StatusCompleted
PhasePhase 1
SponsorAbbVie
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial completed
    • Primary and study completion dates changed from estimate of Oct 2026 to Oct 5, 2026
  2. Notable Eligibility criteria expanded, about 17 words Show 4 more changesShow less
    • Primary endpoints: details revised at 1 of 6 entries
    • Enrollment closed, study ongoing
    • Primary and study completion dates: Sep 2026 to Oct 2026
    • Site details revised
  3. Notable Recruitment opened
    • Study sites: 0 to 1
    • Start date changed from estimate of Jun 28, 2026 to Jun 23, 2026
    v2
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Maximum Observed Plasma Concentration (Cmax) of Nacresertib
Timeframe: Up to Day 12
Time to Cmax (Tmax) of Nacresertib
Timeframe: Up to Day 12
Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to the Time of the Last Measurable Concentration (AUCt) of Nacresertib
Timeframe: Up to Day 12
AUC From Time 0 to the Time Infinity (AUCinf) of Nacresertib
Timeframe: Up to Day 12
Terminal Phase Elimination Rate Constant (Beta) of Nacresertib
Timeframe: Up to Day 12
Terminal Phase Elimination Half-Life (t1/2) of Nacresertib
Timeframe: Up to Day 12

Arms and interventions

Period 1: Nacresertib OnlyExperimental

Participant receives single dose of Nacresertib administered on Day 1

Period 2: Nacresertib and ItraconazoleExperimental

Participant will receive itraconazole multiple times on Day 1, followed by a single dose of itraconazole on Days 2 through 11. Participants will also receive a single oral dose of Nacresertib on Day 4.

Drugs: Nacresertib, Itraconazole

Sites

1 site in 1 country

  • Acpru /Id# 282339Grayslake, Illinois, United States